1/28/2008
Chordoma: The Nonsarcoma Primary Bone Tumor
Sarcoma Research Series: The Oncologist
Chordoma: The Nonsarcoma Primary Bone Tumor
Rashmi Chugh, MD, Hussein Tawbi, MD, David R. Lucas, MD, J. Sybil Biermann, MD, Scott M. Schuetze, MD, Laurence H. Baker, MD
Chordomas are rare, slowly growing, locally aggressive neoplasms of bone that arise from embryonic remnants of the notochord. These tumors typically occur in the axial skeleton and have a proclivity for the spheno-occipital region of the skull base and sacral regions. In adults, 50% of chordomas involve the sacrococcygeal region, 35% occur at the base of the skull near the spheno-occipital area, and 15% are found in the vertebral column. Craniocervical chordomas most often involve the dorsum sella, clivus, and nasopharynx. Chordomas are divided into conventional, chondroid, and dedifferentiated types. Conventional chordomas are the most common. They are characterized by the absence of cartilaginous or additional mesenchymal components. Chondroid chordomas contain both chordomatous and chondromatous features, and have a predilection for the spheno-occipital region of the skull base. This variant accounts for 5%–15% of all chordomas and up to 33% of cranial chordomas. Dedifferentiation or sarcomatous transformation occurs in 2%–8% of chordomas. This can develop at the onset of the disease or later. Aggressive initial therapy improves overall outcome. Patients who relapse locally have a poor prognosis but both radiation and surgery can be used as salvage therapy. Subtotal resection can result in a stable or improved status in as many as 50% of patients who relapse after primary therapy. Radiation therapy may also salvage some patients with local recurrence. One series reported a 2-year actuarial local control rate of 33% for patients treated with proton beam irradiation.
To get a complete version of this article, Follow this link
|
|
 |
Thursday, June 29, 2000
Managing Chemotherapy Side Effects Can Lead to a Summer of Strength
view
|
Friday, November 10, 2000
Synovial Sarcoma: A Clinicopathologic, Staging, and Prognostic Assessment
view
|
Friday, January 03, 2003
Insulin-like growth factor-I receptor activation blocks doxorubicin cytotoxicity in sarcoma cells
view
|
Thursday, April 10, 2003
Synovial Sarcoma of Childhood and Adolescence: A Multicenter, Multivariate Analysis of Outcome
view
|
Sunday, May 01, 2005
Antitumor Activity of the Insulin-Like Growth Factor-I Receptor Kinase Inhibitor NVP-AEW541 in Musculoskeletal Tumors
view
|
Thursday, May 05, 2005
A Look At Bone Sarcomas Past and Present
view
|
Wednesday, August 10, 2005
Rhabdomyosarcoma: New Windows of Opportunity
view
|
Sunday, September 04, 2005
The Growing Role of the mTOR Pathway
view
|
Monday, September 12, 2005
Cancer Treatment Related Changes in Cognitive Function (a.k.a. "Chemo Brain")
view
|
Tuesday, July 04, 2006
New Emerging Drugs in Soft Tissue Sarcoma
view
|
Thursday, August 24, 2006
The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights
view
|
|
Tuesday, September 05, 2006
Soft Tissue Sarcoma
|
Thursday, January 25, 2007
Cancer Pathway Exposed
view
|
Sunday, May 20, 2007
Multiple Drug Resistance in Osteogenic Sarcoma: INT0133 From the Children's Oncology Group
view
|
Monday, May 28, 2007
Gemcitabine and Docetaxel in Metastatic Sarcoma: Past, Present, and Future
view
|
Wednesday, July 11, 2007
Survival for Soft Tissue Sarcoma Patients Improved at High-volume Centers
view
|
|
Tuesday, September 04, 2007
Anatomy of a Visit - Behind the Waiting Room Walls in the UM Cancer Center
|
Wednesday, September 12, 2007
Kaposi Sarcoma
view
|
Thursday, September 13, 2007
Ewing Sarcoma
view
|
Thursday, November 08, 2007
Gastrointestinal Stromal Tumours and Imatinib
view
|
|
Friday, November 09, 2007
13th Annual CTOS SARC Agenda Book
|
Friday, November 16, 2007
Pediatric sarcomas occurring in adults
view
|
Wednesday, January 02, 2008
SARC: An Effort to Perform Clinical Trials More Efficiently and Effectively for People with Sarcoma
view
|
Saturday, January 05, 2008
Therapeutic Potential of Directed Tyrosine Kinase Inhibitor Therapy in Sarcomas
view
|
Monday, January 28, 2008
Chordoma: The Nonsarcoma Primary Bone Tumor
view
|
|
|
|